MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Stryker to pay $1.3B for Physio-Control

Stryker to pay $1.3B for Physio-Control

By

Stryker acquires Physio-ControlStryker (NYSE:SYK) said today that it agreed to pay $1.28 billion to Bain Capital for automated external defibrillator maker Physio-Control.

Medtronic (NYSE:MDT) sold Physio-Control to Bain for $478 million in January 2012.

The all-cash deal, slated to close at the beginning of the 2nd quarter, is expected to add slightly to Kalamazoo, Mich.-based Stryker’s adjusted earnings per share this year. The company boosted its earnings outlook for the year to reflect contributions from Physio-Control and recent buy Sage Products, saying it now expects to post adjusted EPS of $5.57 to $5.77, up from guidance for $$5.55 to $5.75. The acquisitions are forecast to contribute 15¢ to 18¢ to adjusted EPS next year, Stryker said.

Redmond, Wash.-based Physio-Control, which put up sales of $503 million during fiscal 2015, is due to be integrated into Stryker’s emergency medical systems portfolio, the company said.

“Physio-Control has achieved global leadership positions with a strong brand and customer-centered solutions that can predict or intervene in life-threatening emergencies,” chairman & CEO Kevin Lobo said in prepared remarks. “Physio-Control’s focused strategy and their culture will fit well within the EMS business of our medical division, further leveraging our existing call pattern. We look forward to welcoming the Physio-Control team to Stryker.”

“Joining Stryker is an exciting next step in the evolution of Physio-Control for both our team and our customers,” added Physio-Control president & CEO Brian Webster. “Stryker has a deep understanding of capital equipment and of our core market segments. We will build on the success our team has achieved in partnership with Bain Capital, and further accelerate the execution of our strategy, including continued investment in great product solutions for our customers.”

“It has been a privilege to work collaboratively with Brian and the management team as the company has shown great progress and built even more enduring customer loyalty,” Bain managing director Chris Gordon said. “Physio-Control has added significant operational strength and made substantial investments in R&D to accelerate the development and launch of its next generation product lines. We believe the business is well positioned for further growth, and are confident that Physio-Control will continue to thrive under Stryker’s ownership.”

In case you missed it

RSS From Medical Design & Outsourcing

  • GE warns of supply chain strain well into 2022
    Medical device makers and suppliers seeking relief from the global semiconductor shortage will have to hold on a while longer. GE (NYSE:GE) is warning investors that supply and labor shortages are squeezing its Healthcare business this quarter, and that the pressure won’t likely let up in 2021. GE’s Healthcare business “largely is a supply chain… […]
  • Theranos whistleblower testifies to blood analyzer inaccuracies in Elizabeth Holmes fraud trial
    One of Theranos’ whistleblowers testified on the inaccuracies in the blood analyzers that Theranos had touted to investors on the third day of Elizabeth Holmes’ federal fraud trial. Erika Cheung, a former Theranos lab associate, testified yesterday that the machines the company was using to conduct patient blood tests had inaccuracies of quality control test… […]
  • CMS aborts launch of MCIT payment program for breakthrough devices
    CMS intends to kill the Medicare Coverage of Innovative Technology (MCIT) program that would have accelerated government payments for medical devices designated by the FDA as breakthroughs. CMS (the U.S. Centers for Medicare & Medicaid Services) disclosed its proposal in the Federal Registrar yesterday — three months before the rule was set to take effect… […]
  • One of FDA’s top lawyers leaves to join Greenberg Traurig
    Greenberg Traurig recently announced that James C. Fraser, a former associate chief counsel for litigation at the FDA, has joined its Litigation and Health Care & FDA practices in Washington, D.C. Fraser left FDA in August. He has more than 16 years of experience in life sciences litigation and most recently worked in conjunction with… […]
  • September 2021 Issue: Our latest Medical Device Handbook is out!
      Making medical devices: Everything you need to know The innovation-fueled evolution of drug eluting stents Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’ Getting the inside scoop behind top medtech innovations Autumn is upon us, and it is once again time to sip a pumpkin spice latte  — or a pumpkin beer —… […]
  • Steris launches two new vaporized hydrogen peroxide biodecontamination systems
    Steris has launched the next generation of its vaporized hydrogen peroxide (VHP) biodecontamination systems to achieve 6-log bioburden reduction in good-manufacturing-practice pharmaceutical, medical device and research environments. It’s possible to integrate the new VHP 100i and 1000i systems into a facility’s building automation and HVAC systems, running a decontamination cycle at programmed intervals or at… […]
  • First witnesses in Elizabeth Holmes federal fraud trial take the stand
    Two of the prosecution’s witnesses took the stand yesterday on the second day of Elizabeth Holmes’ federal fraud trial. Theranos’ former financial controller San Ho Spivey, who is referred to as Danise Yam, took the stand and testified about the company’s financial condition during its heyday. Yam told Assistant U.S. Attorney Robert Leach that Theranos… […]
  • Axonics loses IP challenge to Medtronic patents
    Medtronic (NYSE:MDT) announced that it picked up three victories in an intellectual property (IP) dispute against Axonics (NSDQ:AXNX) over sacral neuromodulation devices. According to a news release, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected Axonics’ attempt to invalidate three Medtronic patents in its IP infringement lawsuit related to Medtronic’s InterStim neuromodulation device… […]
  • Cepheid wins EUA for new version of COVID-19, flu, RSV combination diagnostic
    Cepheid announced today that it received FDA emergency use authorization (EUA) for its Xpert Xpress CoV-2/Flu/RSV Plus diagnostic. Sunnyvale, California-based Cepheid designed its Xpert Xpress Plus as a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B and respiratory syncytial virus (RSV). Get the full story at our… […]
  • Stratasys expands anatomical modeling services for healthcare
    Stratasys Direct Manufacturing now offers anatomical modeling and consultative services for the healthcare industry. The Stratasys (NASDAQ: SSYS) subsidiary opened its new Healthcare Print Center in Eden Prairie, Minnesota, and soft-launched the new offerings with an invite-only beta test for medical device manufacturers. Over the past 13 weeks, Stratasys J750 Digital Anatomy printers have created… […]
  • FDA clears NeuroOne’s Evo sEEG electrode
    NeuroOne Medical Technologies (NMTC) announced that it received FDA 510(k) clearance for its Evo sEEG electrode technology. Eden Prairie, Minnesota-based NeuroOne’s Evo sEEG electrode technology received clearance for temporary (less than 24 hours) use with recording, monitoring and stimulation equipment for the recording, monitoring and stimulation of electrical signals at the subsurface level of the brain,… […]